UPIIIa Double Nickase Plasmid (h): sc-401796-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UPIIIa Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- UPIIIa Double Nickase Plasmid (h) and UPIIIa Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting UPK3A. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: UPIIIa Antibody (C-6): sc-166808
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UPIIIa Double Nickase Plasmid (h) | sc-401796-NIC | 20 µg | $410.00 | |||
UPIIIa Double Nickase Plasmid (h2) | sc-401796-NIC-2 | 20 µg | $410.00 |
UPK3A encodes uroplakin IIIa (UPIIIa), a type I membrane glycoprotein that assembles with other uroplakins to form urothelial plaques on the apical surface of bladder umbrella cells. This complex supports epithelial barrier integrity, membrane specialization, and responses to mechanical stretch, contributing to urothelial differentiation and tissue homeostasis. Altered uroplakin expression patterns are frequently used as indicators of urothelial state and lineage identity in studies of bladder development and pathology. UPK3A-related perturbations are therefore relevant to research on urothelial barrier dysfunction, epithelial remodeling, and molecular phenotypes associated with bladder disease contexts.
UPIIIa Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the UPK3A locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within UPK3A. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt UPK3A function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of UPK3A-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.